Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Extrawell Pharmaceutical Holdings Limited ( (HK:0858) ) just unveiled an announcement.
Extrawell Pharmaceutical Holdings Limited has announced a major transaction involving the Fourth Amendment Deed with Starcoin, which proposes changes to the terms and conditions of existing bonds. These amendments include adjustments to the principal amount, conversion price, interest rate, and maturity date of the bonds. The transaction is significant, as it constitutes a major transaction under the Listing Rules, requiring shareholder approval. The announcement highlights the company’s ongoing efforts to manage its financial instruments and obligations, reflecting its strategic focus on optimizing financial terms and conditions to align with its business goals.
The most recent analyst rating on (HK:0858) stock is a Hold with a HK$0.09 price target. To see the full list of analyst forecasts on Extrawell Pharmaceutical Holdings Limited stock, see the HK:0858 Stock Forecast page.
More about Extrawell Pharmaceutical Holdings Limited
Extrawell Pharmaceutical Holdings Limited operates in the pharmaceutical industry, focusing on the development, manufacture, and sale of pharmaceutical products. The company is engaged in providing a range of healthcare solutions and has a market focus on enhancing its product offerings and expanding its reach.
Average Trading Volume: 2,678,032
Technical Sentiment Signal: Hold
Current Market Cap: HK$209.1M
See more insights into 0858 stock on TipRanks’ Stock Analysis page.